Novartis' radioligand therapy Lutathera could soon face generic competition
The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...
Novartis' radioligand therapies are shipped in green lead-shielded canisters (Novartis) April 23, 2026 01:49 PM EDTUpdated April 23, 11:06 PM PharmaIn FocusManufacturing Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete? Nicole DeFeudis Senior Reporter The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s … Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that